)
Montse Daban
Executive Director,
BIOCAT
Director of Strategic Foresight and International Relations at Biocat (BioRegion of Catalonia).
Degree in Biology, PhD in Molecular Biology, Master's Degree in Science Communication, Executive Master’s Degree in Diplomacy and Foreign Affairs.
Research in Life Sciences (1987 - 1999) and Science Communication (1996-1999) in Barcelona, Lille (France) and Cleveland (OH,USA).
Since 2006 (2006-2011&2018-present), holding different positions at Biocat (Communications, Science Policies and International Relations). Former Adviser on R&I policies and International Relations for the Government of Catalonia, at the Department of Research and Universities (formerly Secretariat) (2011-present). Science editor (2000-2006), Rubes Editorial.
President of the Council of European BioRegions (CEBR, 2022). Member of the Board of Directors of the European Clusters Allilance (ECA ). EIT Health Innostars Expert and Mentor.
Degree in Biology, PhD in Molecular Biology, Master's Degree in Science Communication, Executive Master’s Degree in Diplomacy and Foreign Affairs.
Research in Life Sciences (1987 - 1999) and Science Communication (1996-1999) in Barcelona, Lille (France) and Cleveland (OH,USA).
Since 2006 (2006-2011&2018-present), holding different positions at Biocat (Communications, Science Policies and International Relations). Former Adviser on R&I policies and International Relations for the Government of Catalonia, at the Department of Research and Universities (formerly Secretariat) (2011-present). Science editor (2000-2006), Rubes Editorial.
President of the Council of European BioRegions (CEBR, 2022). Member of the Board of Directors of the European Clusters Allilance (ECA ). EIT Health Innostars Expert and Mentor.
Sessions
-
03-Sep-2025Panel: The state of the CGT industry & turning the future into action
-
03-Sep-2025Panel: Is decentralised manufacturing the way to cost effectiveness?
-
03-Sep-2025Spain’s biotech leap: Manufacturing, clinical capacity & EU integration
-
04-Sep-2025Theatre 1: Panel: Charting the way forward: Where are we heading?
-
10-Feb-2026Theatre 3What does a ‘Trial Ready’ Therapeutic look like in 2026?
-
11-Feb-2026Theatre 4Clinical data thresholds, funding strategies and risk management